PepVault
/ database / IGF Analog

IGF-1 LR3

Also: Long R3 IGF-1

Long-acting IGF-1 analog — anabolic but raises systemic IGF-1 markedly.

Evidence
emerging
Legal status
research only
Half-life
~20-30 hours
Routes
subq
View on Limitless LifeAdd to compare
What it is

IGF-1 LR3 has an extra 13 amino acids at the N-terminus and a single substitution that reduces binding to IGFBPs. The result is a much longer half-life and stronger anabolic signal than native IGF-1.

Mechanism

Modified IGF-1 with reduced IGFBP binding, dramatically extending half-life.

Outcomes it's matched to
Safety

Hypoglycemia risk; theoretical cancer risk from sustained IGF-1 elevation.

  • Active malignancy
  • Diabetes (without supervision)
Legal context

Research use only. WADA-prohibited.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault